Development and regulation of exosome‐based therapy products

Abstract

Recently, various innovative therapies involving the ex vivo manipulation and subsequent reintroduction of exosome-based therapeutics into humans have been developed and validated, although no exosome-based therapeutics have yet to be brought into the clinic. Exosomes are nanosized vesicles secreted by many cells that utilize them for cell-to-cell communications to facilitate transport of proteins and genetic material. Comprised of cellular membranes with multiple adhesive proteins on their surface, exosomes offer distinct advantages that exceptionally position them as highly effective drug carriers. Additionally, exosomes can exert unique biological activity reflective of their origin that may be used for therapy of various diseases. In fact, exosomes have benefits of both synthetic nanocarriers and cell-mediated drug delivery systems, and avoid their limitations. This concise review highlights the recent developments in exosome-based drug delivery systems and the main regulatory considerations for using this type of therapeutic in clinic. WIREs Nanomed Nanobiotechnol 2016, 8:744-757. doi: 10.1002/wnan.1395 For further resources related to this article, please visit the WIREs website.

Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy

“…One may speculate that mechanism 1) and 2), as well as 3) and 4) are complementary in that the secretion of a particular factor may be a loss for the donor and gain for the recipient cell. As a shared consequence of these distinct mechanisms, circulating EVs contain miRNAs or proteins critical for MDR and can be analyzed for cancer diagnosis and targeted chemotherapy in personalized nanomedicine (for reviews, see (Batrakova & Kim, 2016; Bell, Kirk, Hiltbrunner, Gabrielsson, & Bultema, 2016; Fais et al, 2016; Mirzaei, Sahebkar, Jaafari, Goodarzi, & Mirzaei, 2017; A. Sharma, 2017; A.…”

The potential of exosomes as theragnostics in various clinical situations

“…Fig. 2 shows the overall scheme of different modalities for using exosome-based formulations (see [89]).…”

“…The relatively tight and ordered lipid bilayer impedes efficient loading of drugs into EVs without reducing membrane integrity. Such damage might alter the immune-oriented characteristics of EVs and make them visible to the mononuclear phagocyte system (see [89]). Therefore, ideal loading methods should not only possess high loading efficiency but also preserve the structural integrity of EVs and the functional integrity of therapeutics (see [83]).…”

Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis

“…The use of MSC derivatives for treatment holds several advantages over the use of a live MSC population. They can be less costly to produce and can last up to 6 months when stored at −20 °C [61]. Derivatives are also a safer treatment option compared with whole MSCs as there are no risks associated with mutagens or oncogenicity.…”